160 related articles for article (PubMed ID: 32458743)
1. Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report.
Zielli T; Gnetti L; Buti S
Tumori; 2020 Dec; 106(6):NP79-NP83. PubMed ID: 32458743
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
Motzer RJ; Hutson TE; Glen H; Michaelson MD; Molina A; Eisen T; Jassem J; Zolnierek J; Maroto JP; Mellado B; Melichar B; Tomasek J; Kremer A; Kim HJ; Wood K; Dutcus C; Larkin J
Lancet Oncol; 2015 Nov; 16(15):1473-1482. PubMed ID: 26482279
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
Glen H
Future Oncol; 2016 Oct; 12(19):2195-204. PubMed ID: 27339111
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
[TBL] [Abstract][Full Text] [Related]
5. The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review.
Schwartz C; Pfanzelter N; Kuzel TM
Clin Genitourin Cancer; 2017 Oct; 15(5):e903-e906. PubMed ID: 28624319
[No Abstract] [Full Text] [Related]
6. The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy.
Hamieh L; Beck RL; Le VH; Hsieh JJ
Clin Genitourin Cancer; 2020 Aug; 18(4):252-257.e2. PubMed ID: 32291161
[TBL] [Abstract][Full Text] [Related]
7. Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.
Lee CH; Motzer RJ; Glen H; Michaelson MD; Larkin J; Minoshima Y; Kanekiyo M; Ikezawa H; Sachdev P; Dutcus CE; Funahashi Y; Voss MH
Br J Cancer; 2021 Jan; 124(1):237-246. PubMed ID: 33024271
[TBL] [Abstract][Full Text] [Related]
8. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
De Lisi D; De Giorgi U; Lolli C; Schepisi G; Conteduca V; Menna C; Tonini G; Santini D; Farolfi A
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):461-467. PubMed ID: 29557694
[TBL] [Abstract][Full Text] [Related]
10. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
Hutson TE; Michaelson MD; Kuzel TM; Agarwal N; Molina AM; Hsieh JJ; Vaishampayan UN; Xie R; Bapat U; Ye W; Jain RK; Fishman MN
Eur Urol; 2021 Aug; 80(2):162-170. PubMed ID: 33867192
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study.
Matsubara N; Naito Y; Nakano K; Fujiwara Y; Ikezawa H; Yusa W; Namiki M; Okude T; Takahashi S
Int J Urol; 2018 Nov; 25(11):922-928. PubMed ID: 30129060
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib for the treatment of kidney cancer.
Študentová H; Vitásková D; Melichar B
Expert Rev Anticancer Ther; 2018 Jun; 18(6):511-518. PubMed ID: 29737893
[TBL] [Abstract][Full Text] [Related]
13. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).
Molina AM; Hutson TE; Larkin J; Gold AM; Wood K; Carter D; Motzer R; Michaelson MD
Cancer Chemother Pharmacol; 2014 Jan; 73(1):181-9. PubMed ID: 24190702
[TBL] [Abstract][Full Text] [Related]
14. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.
Motzer RJ; Hutson TE; Ren M; Dutcus C; Larkin J
Lancet Oncol; 2016 Jan; 17(1):e4-5. PubMed ID: 26758760
[No Abstract] [Full Text] [Related]
15. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
[TBL] [Abstract][Full Text] [Related]
16. Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.
Grande E; Glen H; Aller J; Argenziano G; Lamas MJ; Ruszniewski P; Zamorano JL; Edmonds K; Sarker S; Staehler M; Larkin J
Expert Opin Drug Saf; 2017 Dec; 16(12):1413-1426. PubMed ID: 28920492
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.
Grünwald V; Powles T; Choueiri TK; Hutson TE; Porta C; Eto M; Sternberg CN; Rha SY; He CS; Dutcus CE; Smith A; Dutta L; Mody K; Motzer RJ
Future Oncol; 2019 Mar; 15(9):929-941. PubMed ID: 30689402
[TBL] [Abstract][Full Text] [Related]
18. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
Feldman DR; Ged Y; Lee CH; Knezevic A; Molina AM; Chen YB; Chaim J; Coskey DT; Murray S; Tickoo SK; Reuter VE; Patil S; Xiao H; Aghalar J; Apollo AJ; Carlo MI; Motzer RJ; Voss MH
Cancer; 2020 Dec; 126(24):5247-5255. PubMed ID: 32975815
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib for the treatment of renal cell carcinoma.
Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
[TBL] [Abstract][Full Text] [Related]
20. The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.
Jacob A; Shook J; Hutson T
Expert Rev Anticancer Ther; 2021 Apr; 21(4):365-372. PubMed ID: 33393393
[No Abstract] [Full Text] [Related]
[Next] [New Search]
